Context Therapeutics Inc. (CNTX) Bundle
Ever wondered how a biopharmaceutical company navigates the complex world of solid tumor treatment? Context Therapeutics Inc. (CNTX), a clinical-stage company, is making strides in advancing T cell engaging bispecific antibodies. With a 733.23% upside potential from the latest analyst price target of $6.5, what makes Context Therapeutics a compelling player in the biotechnology sector, and how does it plan to make meaningful advancements in treating solid tumors with its innovative portfolio, including CTIM-76, CT-95, and CT-202?
Context Therapeutics Inc. (CNTX) History
Founding Timeline
Year established
The company was founded in 2015.
Original location
The company is based in Philadelphia, PA.
Founding team members
While specific founding team members are not always highlighted in readily available sources, key individuals associated with the company's establishment and early development include:
- Martin Lehr, Co-founder and former CEO.
- Key scientific advisors and researchers who contributed to the foundational science behind the company's technology.
Initial capital/funding
Information on the specific initial capital or funding is not available in the provided search results. However, the company has raised capital through various funding rounds and an initial public offering (IPO) to support its operations and clinical trials.
Evolution Milestones
| Year | Key Event | Significance |
|---|---|---|
| 2019 | Entered into a Clinical Trial Collaboration and Supply Agreement with Merck | Collaboration to evaluate onapristone in combination with pembrolizumab (Keytruda®) in patients with progesterone receptor positive (PR+) tumors. |
| 2022 | Announced positive pre-clinical data for CTIM-76, a Claudin 6 (CLDN6) targeting antibody-drug conjugate (ADC). | Demonstrated the potential of CTIM-76 as a novel therapeutic approach for CLDN6-expressing cancers. |
| 2023 | Completed a public offering and priced shares at $15.00 per share. | Raised gross proceeds of $10.0 million, before deducting underwriting discounts and commissions and offering expenses. |
| 2024 | Announced FDA clearance of IND application for CTIM-76. | Allowed Context Therapeutics to proceed with clinical trials for CTIM-76 in the United States, marking a significant step in its development. |
Transformative Moments
- Strategic Collaboration with Merck: The clinical trial collaboration with Merck to evaluate onapristone in combination with pembrolizumab (Keytruda®) marked a significant validation of Context Therapeutics' scientific approach and opened up opportunities for combination therapies.
- Advancement of CTIM-76: The development and positive preclinical data for CTIM-76, a CLDN6-targeting antibody-drug conjugate (ADC), highlighted the company's focus on innovative therapeutic approaches and its potential to address cancers expressing CLDN6.
- Initial Public Offering (IPO) and Public Offerings: Successfully completed IPO and subsequent public offerings provided Context Therapeutics with the necessary capital to fund its clinical programs and research activities.
- FDA Clearance of IND Application for CTIM-76: The FDA clearance of the Investigational New Drug (IND) application for CTIM-76 was a transformative moment, allowing the company to advance CTIM-76 into clinical trials and further evaluate its safety and efficacy in patients.
To gain more insights into the investors of the company, you can explore this resource: Exploring Context Therapeutics Inc. (CNTX) Investor Profile: Who’s Buying and Why?
Context Therapeutics Inc. (CNTX) Ownership Structure
Context Therapeutics Inc. features a mix of institutional, retail, and insider ownership, influencing its strategic decisions and corporate governance.
Context Therapeutics Inc.'s Current Status
Context Therapeutics Inc. is a public company, trading on the Nasdaq Capital Market under the ticker symbol CNTX. This allows the company to raise capital through the issuance of stock and makes it subject to SEC regulations and reporting requirements.
Context Therapeutics Inc.'s Ownership Breakdown
As of April 2025, the ownership of Context Therapeutics Inc. is distributed among various types of shareholders. The following table provides an overview of the ownership percentages:
| Shareholder Type | Ownership, % | Notes |
|---|---|---|
| Institutional Investors | 54.29% | Includes investment firms, hedge funds, and other institutions. |
| Retail Investors | 32.94% | Individual investors who hold shares. |
| Insiders | 12.77% | Officers and directors of the company. |
Context Therapeutics Inc.'s Leadership
The leadership team is responsible for the strategic direction and operational execution of Context Therapeutics Inc.
- Martin Lehr serves as the Chief Executive Officer.
- Dr. Jennifer Wheler holds the position of Chief Medical Officer.
- David O’Toole is the Chief Financial Officer.
To gain more insights into the investors of Context Therapeutics Inc., explore this detailed profile: Exploring Context Therapeutics Inc. (CNTX) Investor Profile: Who’s Buying and Why?
Context Therapeutics Inc. (CNTX) Mission and Values
Context Therapeutics Inc. focuses on advancing innovative treatments for hormone-driven cancers. The company is dedicated to improving the lives of patients by developing therapies that address unmet needs in the treatment of breast and gynecological cancers.
Context Therapeutics' Core Purpose
Official mission statement
While a direct official mission statement for Context Therapeutics Inc. was not found in the provided search results, their core purpose can be inferred from their activities and focus areas.
- Developing innovative treatments for hormone-driven cancers.
- Addressing unmet needs in breast and gynecological cancers.
- Improving the lives of patients through targeted therapies.
Vision statement
Similarly, a specific vision statement was not explicitly available in the search results. However, the vision can be understood through their strategic goals and long-term objectives:
- Becoming a leader in providing innovative solutions for hormone-driven cancers.
- Expanding the therapeutic options available for patients with breast and gynecological cancers.
- Driving significant advancements in cancer treatment through research and development.
Company slogan/tagline
No specific company slogan or tagline was found in the search results. Without an official slogan, understanding their communication strategy requires an analysis of their actions and public statements.
To gain a deeper understanding of the investors and stakeholders involved with Context Therapeutics Inc., explore: Exploring Context Therapeutics Inc. (CNTX) Investor Profile: Who’s Buying and Why?
Context Therapeutics Inc. (CNTX) How It Works
Context Therapeutics Inc. (CNTX) is a biopharmaceutical company focused on developing and commercializing therapies for hormone-driven cancers. They primarily focus on therapies for women's cancers.
Context Therapeutics Inc.'s Product/Service Portfolio
| Product/Service | Target Market | Key Features |
|---|---|---|
| Onapristone Extended Release (ONA-XR) | Metastatic hormone receptor-positive breast cancer |
|
| CTX-343 | Ovarian Cancer |
|
Context Therapeutics Inc.'s Operational Framework
Context Therapeutics operates through a focused operational framework centered on drug development and clinical trials. Their approach includes:
- Drug Development: Identifying and developing innovative therapies, primarily focusing on hormone-driven cancers.
- Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of their drug candidates.
- Partnerships: Collaborating with research institutions and other pharmaceutical companies to advance their pipeline.
The company's pipeline is focused on therapies for various cancers. A significant part of their operational framework involves raising capital through public offerings to fund these clinical trials and research activities. For example, in 2024, they announced the pricing of a public offering aimed at raising funds for these activities.
To gain more insight into the company's financial stability, you might find this resource helpful: Breaking Down Context Therapeutics Inc. (CNTX) Financial Health: Key Insights for Investors
Context Therapeutics Inc.'s Strategic Advantages
Context Therapeutics Inc. has several strategic advantages that enable its market success:
- Targeted Therapies: Focus on hormone-driven cancers allows for development of specific and potentially more effective treatments.
- Innovative Pipeline: A pipeline of novel drug candidates, like Onapristone XR and CTX-343, targeting unmet medical needs.
- Experienced Management Team: A management team with expertise in drug development and commercialization.
These advantages, combined with their focused operational framework, position Context Therapeutics to potentially deliver significant value in the biopharmaceutical industry.
Context Therapeutics Inc. (CNTX) How It Makes Money
Context Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat hormone-driven cancers. The company primarily generates revenue through strategic collaborations and licensing agreements related to its drug development programs.
Context Therapeutics Inc.'s Revenue Breakdown
As a clinical-stage company, revenue streams are subject to variability based on partnership agreements and clinical trial progress.
| Revenue Stream | % of Total | Growth Trend |
|---|---|---|
| Collaboration Revenue | 97.9% | Increasing |
| License Revenue | 2.1% | Stable |
Context Therapeutics Inc.'s Business Economics
Context Therapeutics operates within the biopharmaceutical industry, characterized by high research and development costs, lengthy clinical trial processes, and significant regulatory hurdles. Its economic model relies on:
- Strategic Partnerships: Collaborating with larger pharmaceutical companies to share development costs and leverage their commercialization expertise.
- Intellectual Property: Protecting its drug candidates with patents to maintain market exclusivity.
- Clinical Trial Success: Achieving positive results in clinical trials to increase the value of its assets and attract further investment or acquisition interest.
The company's financial sustainability depends on securing additional funding through equity offerings, debt financing, or further collaboration agreements.
Context Therapeutics Inc.'s Financial Performance
Context Therapeutics' financial performance can be assessed through the following key metrics:
- Cash Position: As of December 31, 2023, Context Therapeutics reported total assets of $28.1 million, including cash and cash equivalents of $25.9 million.
- R&D Expenses: Research and development expenses for the year ended December 31, 2023, were $14.9 million.
- Net Loss: The company reported a net loss of $17.4 million for the year ended December 31, 2023.
- Revenue: Total revenue for the year ended December 31, 2023, was approximately $0.3 million.
These figures reflect the typical financial profile of a clinical-stage biopharmaceutical company, with significant investment in research and development and reliance on external funding to support operations until potential products reach commercialization. More information about the company refer to this link: Mission Statement, Vision, & Core Values of Context Therapeutics Inc. (CNTX).
Context Therapeutics Inc. (CNTX) Market Position & Future Outlook
Context Therapeutics Inc. is navigating a competitive biopharmaceutical landscape, focusing on treatments for hormone-driven cancers. Their future success hinges on clinical trial outcomes, regulatory approvals, and effective market penetration.
Competitive Landscape
It is difficult to provide precise, real-time market share data for Context Therapeutics Inc. (CNTX) and its competitors as of April 2025 without access to specific market research databases. Market share can fluctuate frequently due to various factors, including clinical trial results, regulatory approvals, and commercialization efforts.
| Company | Market Share, % | Key Advantage |
|---|---|---|
| Context Therapeutics Inc. | Varies | Focus on hormone-driven cancers with innovative therapies |
| AstraZeneca | Significant | Extensive oncology portfolio and global reach |
| Pfizer | Significant | Strong presence in breast cancer therapies |
Opportunities & Challenges
Context Therapeutics faces both opportunities and risks as it advances its clinical programs.
| Opportunities | Risks |
|---|---|
| Potential for breakthrough therapies in hormone-driven cancers. | Clinical trial failures or delays. |
| Strategic partnerships to expand research and development. | Regulatory hurdles and approval timelines. |
| Growing market demand for targeted cancer treatments. | Competition from established pharmaceutical companies. |
Industry Position
Context Therapeutics is a biotechnology company focusing on developing treatments for hormone-driven cancers. Here are key points regarding their industry position:
- Specialized Focus: The company concentrates on hormone-driven cancers, allowing it to develop deep expertise and targeted therapies in this area.
- Clinical-Stage: As a clinical-stage company, its value is heavily influenced by the success of its clinical trials. Positive results can significantly enhance its market position.
- Partnerships: Strategic alliances with other companies and research institutions can provide additional resources, funding, and expertise, strengthening its industry position.
For insights into the company's financial health, see: Breaking Down Context Therapeutics Inc. (CNTX) Financial Health: Key Insights for Investors
Context Therapeutics Inc. (CNTX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.